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The anatomy, function and embryonic development of the heart have been of interest to clinicians and researchers
alike for centuries. A beating heart is one of the key criteria in defining life or death in humans. An understanding
of the multitude of genetic and functional elements that interplay to form such a complex organ is slowly evolving
with new genetic, molecular and experimental techniques. Despite the need for ever more complex molecular
techniques some of our biggest leaps in knowledge come from nature itself through observations of mutations
that create natural defects in function. Such a natural mutation is found in the Mexican axolotl, Ambystoma
mexicanum. It is a facultative neotenous salamander well studied for its ability to regenerate severed limbs and tail.
Interestingly it also well suited to studying segmental heart development and differential sarcomere protein
expression due to a naturally occurring mendelian recessive mutation in cardiac mutant gene “c”. The resultant
mutants are identified by their failure to beat and can be studied for extended periods before they finally die due
to lack of circulation. Studies have shown a differential expression of tropomyosin between the conus and the
ventricle indicating two different cardiac segments. Tropomyosin protein, but not its transcript have been found to
be deficient in mutant ventricles and sarcomere formation can be rescued by the addition of TM protein or cDNA.
Although once thought to be due to endoderm induction our findings indicate a translational regulatory
mechanism that may ultimately control the level of tropomyosin protein in axolotl hearts.
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Translational repressionIntroduction
The Mexican axolotl, a facultative neotenous salamander,
provides a valuable model to study heart development due
to a cardiac lethal mutation (gene c) that affects only heart
muscle [1,2]. It has also been used extensively for organ
regeneration research, particularly of its limbs and tails [3]
but have included initial studies into the regeneration of
the heart [4]. The axolotl cardiac gene c mutation is a
Mendelian, autosomal recessive lethal mutation with
significant effects on tropomyosin protein levels in the
cardiac tissue. Morphological studies of the abnormal
cardiomyogenesis in mutants have shown they lack or-
ganized myofibrils, have large collections of amorphous
material, but still retain normal electrophysiological
properties [5-7]. The embryos can survive for up to a* Correspondence: dubed@upstate.edu
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reproduction in any medium, provided the orfortnight post-hatching which is ideal for studying this
process before the lack of circulation, secondary to
abnormal sarcomere formation is lethal. The mutant
axolotl heart provides a unique opportunity for studying
the intricate process of cardiac development and for
examining the specific functional role of each tropomyosin
(TM) isoform in this process. Ultimately the protein level
of TM is profoundly diminished in the ventricle of c/c
mutant hearts, resulting in an absence of organized
myofibrils and subsequently the inability to beat [5-8].
It is important to note that the conus is not deficient in
tropomyosin protein, retains organized myofibrils and is
capable of beating independently, unlike the atria and
ventricle in mutant hearts [8]. Notably, the mutant
hearts can be rescued in situ by supplying exogenous
TM protein or TM cDNA in an expression construct
under the control of an appropriate promoter(s) [9,10].
Mutant hearts can also be rescued in situ by a specific
non-coding RNA that is unrelated to TM [11-13].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulates the expression of tropomyosin is yet to be
elucidated. To better understand the mechanism(s)
effecting tropomyosin expression in mutant hearts, we
undertook an extensive molecular characterization of
the various isoforms of tropomyosin in the Mexican
axolotl.
Isoform diversity of tropomyosin in vertebrates
The thin filaments of striated muscle in vertebrate consist
of actin, tropomyosin, the troponin (Tn) complex (Tn-I,
Tn-C and Tn-T), tropomodulin, and a few other proteins
[14]. Actin filaments interaction with Ca +2 governs
muscle contraction and relaxation. Tropomyosin is a
coiled coil actin-binding protein found along the length of
seven actin monomers. A set of four known genes (TPM1,
TPM2, TPM3 and TPM4) that encode tropomyosin in ver-
tebrates [15-19] give rise to various tropomyosin protein
isoforms that play important roles in striated, smooth and
non-muscle cells. There remains even further diversity in
other models such as zebrafish where six tropomyosin
genes have been identified [15]. The creation of different
tropomyosin isoforms occurs through various mecha-
nisms, including the use of different promoters, alternative
mRNA splicing, different 3’ end mRNA processing and
tissue specific translation control [20].
We have cloned and sequenced the cDNA of three
sarcomeric TM isoforms from cardiac tissues. These iso-
forms are designated as TPM1α, TPM1κ, and TPM4α
[21-23] (Table 1). TPM1α, one of nine alternatively
spliced isoforms of the TPM1 gene, is known to be the
major sarcomeric isoform in mammalian hearts [15-19].
We first identified and characterized another alternatively
spliced sarcomeric isoform of the TPM1 gene in axolotl
hearts [22], designated TPM1κ. TPM1α and TPM1κ have
an identical exon composition except for exon 2 where
TPM1κ contains exon 2a instead of exon 2b (Figure 1 and
Table 1). Exon 2a is characteristic of the smooth muscleTable 1 Exon compostion of various high molecular weight T
Nomenclature of various isoforms
of TM referred to in this article










TPM1κ TPM1(α-TM) Novel S
TPM2α TPM2(β-TM) Striated
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TPM4α TPM4(TM4) StrTM4type isoform (TPM1β) of the TPM1 gene (Figure 1 and
Table 1). TPM1κ transcripts and its corresponding protein
are expressed in both axolotl hearts and skeletal muscle
there appears to be a differential translation of the tran-
script. Using qRT-PCR the expression level of TPM1κ
transcripts is higher than TPM1α (ratio α:κ is 0.32) in
adult axolotl hearts although TPM1κ protein is less than
10% of the total sarcomeric TM, as determined by CH1
antibody [24]. The opposite is true in adult skeletal muscle
where the level of TPM1κ transcript is significantly lower
compared to TPM1α (ratio of α:κ > 13) but the level of
TPM1κ protein constitutes ~30% of the total sarcomeric
TM [24] Similarly, the levels of expression of TPM1α and
TPM1κ transcripts in human hearts are comparable but
the actual TPM1κ protein level is only ~5% of the total
sarcomeric TM [25]. Comparatively, TPM1α protein con-
stitutes ~90-95% of the total TM in human hearts [24,25]
while TPM1κ is not expressed in human skeletal muscle
at all [26]. TPM1κ transcripts are also expressed in embry-
onic chicken heart but not in adult heart and skeletal
muscle [27]. It remains unknown if the protein is expressed
since human TPM1κ antibody may not cross-react with
chicken TPM1κ protein [25]. This discrepancy between
transcript and protein levels in the two isoforms in heart
tissue suggests that TPM1κ transcripts may undergo
translational repression.
Accounting for the other tropomyosin genes other
than TPM1, TPM2α (sarcomeric isoform of the TPM2
gene) is also expressed in mammalian hearts in addition
to the previously described TPM1α and TPM1κ The
sarcomeric isoform of the TPM3 gene, TPM3α, is only
expressed in slow-twitch skeletal muscle. No sarcomeric
isoform of the TPM4 gene is expressed in mammalian
striated muscles because the TPM4 gene is truncated in
mammals [15-17]. On the contrary, TPM4α is a major
TM isoform in amphibian cardiac tissues [23,31] and is
the only isoform for sarcomeric TM in adult avian
hearts [27,30,32].M isoforms with old & new nomenclature [15,17,19,28,29]
s isoforms of TM
tly known as












Figure 1 Alternative splicing patterns of TPM1 and TPM4 genes. (a) Exon composition of the TPM1 gene and alternative splicing that
generates two striated muscle specific isoforms -TPM1α and TPM1κ [26]. (b) Exon composition of TPM4 gene (adapted from avian species as
proposed by Fleenor et al. [30] and alternative splicing generate two isoforms in axolotl, TPM4α and a low-molecular weight TPM4 transcript.
Zajdel et al. Regenerative Medicine Research 2013, 1:8 Page 3 of 10
http://www.regenmedres.com/content/1/1/8Sarcomeric tm protein in cardiac mutant axolotl hearts
Among the various myofibril proteins, tropomyosin has
been shown by a variety of experiments to be drastically
reduced in cardiac mutant hearts [2,6,9,12]. Increasing
the intracellular levels of TM in cardiac mutant heart
cells via introduction of FITC-labeled exogenous TM pro-
tein by itself or an expression construct allowing in-vivo
TM production subsequently promoted myofibrillogenesis
(Figure 2) [9]. Control mutant heart stained with CH1
monoclonal antibody specific for sarcomeric TM, dem-
onstrated minimal staining when examined by confocal
microscopy (Figure 2b). However, examination of mutant
heart transfected with an expression construct of murine
TPM1α cDNA under the control of mouse α-MYHC pro-
moter demonstrated the formation of organized myofibrils
(Figure 2c). The results prove mutant hearts are capable
of forming cardiac myofibrils when provided with suffi-
cient levels of tropomyosin protein. This unequivocally
demonstrated the functional defect in the gene “c”mutation is the deficiency in tropomyosin protein al-
though the underlying cause of this functional deficit is
less clear. Interestingly, other myofibril structural proteins
such as actin, myosin and myosin binding protein C
(MyBp-C) were found to be at or near normal levels in
the mutant hearts [5,28] while one protein, tropomodulin
which is intricately related functionally with sarcomere
maturation is increased [33].
The most comprehensive study on the analysis of
sarcomeric tropomyosin protein expression in normal
and mutant axolotl hearts were reported by Zhang et al.
[12]. To determine whether multiple isoforms of tropomy-
osin exist in embryonic axolotl hearts and to verify if they
are differentially regulated in mutant hearts, 2D western
blot with the monoclonal antibody (CH1), was performed.
Five different protein spots (tropomyosin isoforms)
from both normal and mutant embryonic hearts at
stages 36 to 42 were detected (Figure 3). All isoforms of
tropomyosin detected by the sarcomer specific CH1
Figure 2 Sarcomeric tropomyosin expression in normal, mutant, and TPM1α -transfected mutant hearts. a. Confocal micrograph of
stage-39 normal hearts stained with CH1 anti-tropomyosin antibdody (and rabbit anti-mouse lissamine rhodamine secondary antibody),
well-organized sarcomeric myofibrils can be seen throughout the ventricle of the heart (arrow). b. Heart from stage-39 mutant embryo stained
with CH1 does not show any organized myofibril, Only small areas of amorphous staining can be visualized within the ventricle (arrow).
c. Stage-36 mutant heart lipofected with an expression construct containing a murine TPM1α cDNA under the control of α-Myosin Heavy Chain
promoter, which subsequently induced TM and promoted myofibrillogenesis. Mutant heart stained with α-actinin primary antibody.
Well-organized sarcomeric myofibrils can be seen throughout the heart (arrows). Staining of the Z-lines confirmed the sarcomeric organization
seen in TPM1α transfected hearts that were stained with tropomyosin primary antibody (results not shown here) [ref]. Interestingly, statge-36
mutant heart tansfected with a murine TPM2α cDNA under the same promoter did express some TM protein but sarcomeric myofibrils did not
form throughout the heart in contrast to TPM1α transfected hearts [7].
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lecular weight of ~38 kD. The results showed protein
levels of the 4 CH1 recognized TM isoforms were de-
creased significantly in mutant hearts compared to normal
hearts (Figure 3a and 3b) [12].
Although mutant axolotl hearts are deficient in sarco-
mere specific TM proteins, mRNA levels of each of
three striated muscle isoforms (TPM1α, TPM1κ, and
TPM4α) are comparable in normal and mutant hearts
[12,23]. Hence, the tropomyosin deficiency in mutant
heart is not due to an insufficiency in transcription or
post-transcriptional splicing [23]. We cloned and se-
quenced cDNAs of three isoforms from mutant hearts;
no mutation(s) was detected in any of these cDNAs that
may cause truncated non-functional TM isoform(s). Add-
itionally, we have cloned and sequenced the promoter re-
gion of the TPM4 gene from the DNA isolated from
normal and mutant axolotl hearts and again, no differ-
ences were observed [34]. Hence, the possibility ofFigure 3 2-D Western blot analysis of normal and mutant axolotl hea
4 different CH1-recognizable TM isoforms #1, #2, #3, and #4). b. Mutant hea
hearts at much lower levels along with an extra isoform (#5). #5 isoform is
shown). The top right corner represents an overexposed blot B [12]. The figinsufficient transcription of the cardiac specific TPM4α
isoform is highly unlikely. The most plausible explanation
based on available evidence of TM deficiency in mutant
hearts is a translational insufficiency of the tropomyosin
transcripts in mutant hearts [12].
Molecular analysis and manipulation of tropomyosin
isoforms in normal and mutant axolotl hearts
As stated earlier, there are at least three striated muscle
isoforms of tropomyosin present in the axolotl. Two iso-
forms of tropomyosin cDNA have been identified which
apparently are derived from the single alpha-tropomyosin
gene (TPM1) through alternative splicing [21,22]. Spinner
et al. [23] cloned another tropomyosin cDNA, which is
the product of a TM4 type tropomyosin gene from axolotl
heart. An expression construct with each of these isoforms
upon transfection into mutant hearts canaugment tropo-
myosin proteinlevels and promotes myofibrillogenesis.
The important question is whether or not any one of theserts using CH1 monoclonal antibody. a. Stage-36 normal hearts show
rt at stage-36 all show 4 CH1-recognizable TM isoforms as in normal
detectable in normal hearts at later developmental stages (results not
ure was adapted from Zhang et al. [12].
Figure 4 Transfection of isoform-specific sense and anti-sense
oligonucleotides in the ventricle of normal hearts. a. Confocal
microscopy of normal axolotl hearts transfected with TPM1a anti-sense
oligonucleoted and subsequently stained with CH1 monoclonal
antibody. TPM1a anti-sense oligonucleotide did not result in a
drastic disruption of organized myofibrils in the ventricle, which is
comparable with the normal untreated control hearts (figure not
shown). Sarcomeric TM can be seen in most of the cells. Contractility of
the anti-sense treated hearts were not affected. b. TPM1κ anti-sense
transfection disrupted the myofibril organization in normal axolotl heart
compared to TPM1κ sense transfection. Very little organized structure is
seen when examined by the tropomyosin staining. The secondary
antibody is contained within amorphous areas in the cells. c. It
shows that the TPM1κ sense oligonucleoides did not affect the
structure. Since no effect on myofibril structure with TPM1κ sense
was observed, we tagged the oligonucleotide with FITC (green) to
verify its presence and found it to be within the myocytes. Double
staining of the nucleus (green) and the myofibrils at the periphery
of the cells (red) can be seen. The green staining is ovoid in shape
and primarily located at the center of the cells [10]. Confocal z-series
images of stage ~38 embryonic axolotl hearts transfected with either
TPM1κ anti-sense or sense oligonucleotides. Immunodetection of
sarcomeric tropomyosin using CH1 monoclonal antibody is shown
in red. The results depicted by this figure suggests that TPM1κ plays
a critical role in maintaining the myofibrillar structure in embryonic
axolotl hearts.
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sary for myofibrllogenesis in axolotl hearts in vivo. In
order to address this issue we developed procedures for
disruption of myofibrils in normal axolotl hearts mim-
icking the mutant hearts by lipofecting antibodies against
sarcomeric TM into normal hearts in situ. Myofibrils in
lipofected normal hearts indeed became greatly disorga-
nized [10,35]. As CH1 antibodies react with all three
sarcomeric tropomyosins, it is not possible to evaluate
the requirement of a particular isoform that is involved
in cardiac myofibrillogenesis. Later we developed anti-
body against TPM1κ in rabbits using a 15-mer peptide
sequence (LDELHKSEESLLTAD) derived from axolotl
exon 2a [36]. Recall, TPM1κ is unique as a sarcomeric
TM in that it contains exon 2a instead of exon 2b which
is found in TPM1α. The affinity purified anti-TPM1κ
antibody upon transfection could disarray the organized
myofibrils in axolotl hearts [37]. The results strongly
suggest that TPM1κ plays a critical role in myofibril
formation in axolotl hearts.
Additionally, isoform specific sense and anti-sense
oligonucleotide was transfected into normal axolotl
hearts. TPM1κ expression was blocked in whole embry-
onic axolotl heart by transfection of exon 2a-specific
anti-sense oligonucleotide (Figure 4b). In contrast, myofi-
brils were unaffected in normal control heart when trans-
fected with FITC label sense oligonucleotides (Figure 4c).
RNA was isolated from treated and untreated hearts and
subsequently RT-PCR was carried out with isoform spe-
cific primer-pairs. The results confirmed the lower
Figure 5 Effect of transfection of TM isoform-specific sense- and
anti-sense oligonucleotides on myofibril organization in hearts
from normal axolotl hearts. a. Stereo anaglyph of a 24 section
confocal laser scanning microscope z-series of normal axolotl heart
stained with CH1 anti-tropomyosin antibody. This type of image is
shown because it demonstrates branching myofibrils in whole hearts.
b. Stereo anaglyph of normal hearts transfected with TPM4α exon
2- specific anti-sense, 5′-T*A*C*T*AGCTCGTCCTCAAGC*T*G*C*-3′,
where N* represents the phophothioate blocked oligonucleotide.
Myofibirl organization was disrupted in a majority of the cardio-
myocytes. Most of the tropomyosin appears to be in amorphous
areas when expressed. Some of the cells do not appear to have a
detectable level of tropomyosin. Gross morphology was normal
and the cells appeared to be intact although myofibril structure
was largely disrupted. The contractility was diminished significantly
[36]. c. Normal heart transfected with TPM4α exon 2-specific sense
chimeric olighonucleotide, 5′-fG*C*A*GCTTGAAGGCGAGC
TA*G*T*A*-3, where *N represents phosphothioate blocked
nucleotide, and fG represents G tagged with Fluorescein at the
5′end. This image is a compressed z-series of 2 sections that was
not stereo offset but used to demonstrate double staining. Isolated
pieces of myofibrils that were contained within these sections of
the cardiac cells were stained with tropomyosin antibody (re,
arrowheads). This image is primarily useful for demonstrating the
presence green fluorescence (GFP) within the nuclear area of the
cariomyocytes by five days (asterik). Hoescht staining of the nuclei
in the same heart coincided with the FITC staining that were
localized in a majority of nuclei (figure not shown). The figure was
adapted from Spinner et al. (2004) [36].
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hearts. The conclusion was substantiated by the in vitro
analysis of the specificity of the TPM1κ anti-sense oligo-
nucleotides used in this study. Confocal analysis of the
sense and anti-sense oligonucleotide transfected normal
axolotl hearts was carried out after staining with anti-
tropomyosin antibody (CH1). Immunohistochemical ana-
lysis unequivocally confirmed that the inhibition of the ex-
pression of TPM1κ disrupted myofibril structure of the
myofibrils in anti-sense transfected normal axolotl hearts.
In contrast, TPM1α anti-sense oligonucleotide did not
cause a disruption of the myofibrillar organization in axo-
lotl hearts (Figure 4a).
In a separate study, we found that the antisense TPM4α
oligonucleotide disrupted myofibril formation and inhib-
ited beating in normal axolotl hearts, while the sense
strands did not. A fluorescein-tagged sense oligonucleo-
tide clearly showed that the oligonucleotide was intro-
duced within the cells of intact hearts. The results
implicate the essential role of TPM4α in cardiac myofibril-
logenesis (Figure 5) [8,10,36].
Differential expression of tropomyosin in conus and the
ventricle
Despite the dramatic and lethal effects of the homozy-
gous cardiac gene “c” mutation in the axolotl ventricle,
the conus of the heart beats and has organized myofi-
brils (Figure 6). In order to understand whether various
Figure 6 (See legend on next page.)
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Figure 6 Tropmodulin but not tropomyosin found in cardiac “c” mutant axolotl ventricle. CH1 anti-sarcomeric TM antibody labels the
conus but not the ventricle in stage 38/39 cardiac mutant axolotl hearts. Stage 38/39 normal (a–c) and mutant (d–f) axolotl hearts were double
stained for immunofluorescent microscopy with CH1 anti-sarcomeric TM antibody (FITC channel) and polyclonal anti-tropomodulin antibody,
R1749 (Rhodamine channel). Only the FITC channel is shown for whole heart images (a, d) demonstrating the lack of staining in the ventricle of
mutant hearts while all higher magnification images utilize a dual rhodamine-FITC filter. Letter labeled boxes in A and D correspond with the
area shown in their respective higher magnification image. TM labeled with CH1 antibody is found in a cross-striated pattern in the ventricle
of normal hearts (c) and in the conus of both normal (b) and mutant (e) hearts. Tropomyosin staining is markedly absent in mutant ventricle
(f) resulting in a failure of normal sarcomere formation with tropmodulin found in linear arrays near the surface of the membranes (Arrows, F).
Scale Bar = 100 μm.
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segments of the heart and whether the known TM iso-
forms contribute to myofibril formation in a segment
specific manner, we employed anti-sense oligonucleotides
to separately knockdown post-transcriptional expression
of TPM1α and TPM4α in axolotl heart segments. We
evaluated the organization of myofibrils in the conus and
ventricle of normal and cardiac mutant hearts using im-
munohistochemical techniques. We concluded that the
TPM1α isoform, a product of the TPM1 gene, was essen-
tial for myofibrillogenesis in the conus, whereas TPM4α,
the striated muscle isoform of the TPM4 gene, was essen-
tial for myofibrillogenesis in the ventricle. Our results sup-
port the segmental theory of vertebrate heart development
and suggest the conus is a different transcriptional tissue
unit. Since the conus is an outflow tract structure and in
humans is a conical pouch of the right ventricle from
which the pulmonary artery arises it will be interesting to
examine tropomyosin isoform diversity in these two seg-
ments in other systems including humans [8]. Develop-
ment of the conus appears to be unaffected in the mutant
heart and is comparable to the normal heart. The different
functions of the heart segments would suggest that differ-
ent isoforms could be needed in accordance with that
function. The physiologic characteristics necessary for the
ventricle versus the conus and subsequent outflow tract
are different [38]. Isoform diversity in specific heart seg-
ments includes tropomyosin but also could include other
sarcomeric proteins such as myosin heavy chain [39] Fur-
ther studies could examine the localization and function
of specific isoforms in adult heart segments. There has
also been research on isoform diversity and the relation-
ship to diseases such as dilated cardiomyopathy [25].
These studies suggest that with changing physiologic pa-
rameters, the isoforms can also be changed. Ultimately,
the study of segment specific tropomyosin isoforms may
help in the understanding of time and function specific
sarcomeric proteins and their relationship to regeneration
of heart function in damaged hearts.
Promotion of myofibrillogenesis in mutant hearts in situ
by a non-coding rna
A noncoding RNA, Myofibril-Inducing RNA (MIR) is
capable of promoting myofibrillogenesis and heartbeating in the mutant (c/c) axolotl hearts in situ [11].
Zhang et al. [12] demonstrated that the MIR gene is es-
sential for tropomyosin (TM) expression in axolotl hearts
during development at the level of translation or post-
translation. qRT-PCR using isoform-specific primer-pairs
showed that mRNA expression of three sarcomeric tropo-
myosin isoforms (TPM1α, TPM1κ, and TPM4α) in un-
treated mutant hearts and in normal hearts knocked down
with double-stranded MIR (dsMIR) are similar to un-
treated normal. However, at the protein level, sarcomeric
tropomyosin isoforms detected with CH1 monoclonal
antibodies, are significantly reduced in mutant and dsMIR
treated normal hearts. However, this study neither showed
the mechanism by which MIR may induce sarcomeric TM
synthesis in axolotl hearts nor addressed the role of spe-
cific tropomyosin isoforms in cardiac myofibrillogenesis.
Recently, Kochegarovr et al. [40] randomly cloned RNAs
from fetal human heart. RNA from one of the clones (clone
#291) was found to promote myofibril formation in mutant
axolotl in situ. This RNA induced expression of cardiac
markers in mutant hearts: tropomyosin, troponin and α-
syntrophin. The nucleotide sequences of the cloned RNA
matches in partial with the human microRNA-499a and b,
although it differs in length. qRT-PCR data suggest this
RNA may induce the TPM4α (ATmC-3) isoform in mutant
heart, producing more sarcomeric tropomyosin protein
and subsequently promote myofibril formation. The mech-
anism by which this non-coding RNA induces tropomyosin
in mutant hearts may well be different from that of MIR,
which acts at the post transcriptional level [12].
Review and conclusions
Although our complete understanding of the mechanism
of tropomyosin expression in mutant axolotl hearts as
well as the nature and function of gene “c” is far from
over, we would like to end this review with a positive
note. Our finding of sarcomeric TM isoform TPM1κ in
axolotl led to the discovery of this isoform in human
hearts [26]. Unlike in axolotl, it is not expressed in hu-
man skeletal muscle. Most importantly, an upregulation
of TPM1κ protein has been reported in hearts from
human dilated cardiomyopathy patients [25]. However, it
is not yet known whether the upregulation of TPM1κ is
the cause or a consequence of cardiomyopathy in this
Zajdel et al. Regenerative Medicine Research 2013, 1:8 Page 9 of 10
http://www.regenmedres.com/content/1/1/8patient. Our anti-sense experiments suggest strongly the
functional significance of TPM1κ in axolotl hearts. In
addition, the lower expression level of TPM1κ protein in
axolotl heart and skeletal muscle [24] and also in human
hearts [25] points towards translational repression of
TPM1κ. Further, upon injection intraperitoneally into
juvenile axolotl, Shz-1, a cardiogenic small molecule, aug-
mented the expression levels of transcripts of TPM1α,
TPM1κ, and TPM4α in hearts. But the increased tran-
script level did not resulted into increased sarcomeric TM
protein expression [41]. Finally, although the transcript
levels of all TPM isoforms in normal and mutant axolotl
heart ventricles are comparable, the proteins of all three
isoforms are diminished significantly. This observation
also point towards the translational repression of TM in
cardiac tissues [42]. The evidence for translational control
of sarcomeric TM in mammalian hearts was originally
came from the works from the laboratory of Dr. David
Wieczorek, University of Cincinnati, Cincinnati, OH
[29,43]. Rethinesamy et al. [29] and Blanchard et al. [44]
independently ablated one of the two alleles of the TPM1
gene in mice that resulted in half of the TPM1α transcripts
in ablated mice hearts compared to wild-type. However,
TPM1α protein level was unchanged in ablated mice
hearts suggesting a higher translational efficiency of
TPM1α transcripts in ablated mice hearts. Again, Rajan
et al. [25] reported that although the level of transcripts
of TPM1α and TPM1κ human hearts is parallel, TPM1κ
protein is only ~5% of the total sarcomeric TM whereas
TPM1α protein constitutes about 90-95% of the total
sarcomeric TM. The results strongly suggest the trans-
lational repression of TPM1κ transcripts in human
hearts. The immediate future goal of our laboratory is
to explore further the translational repression of tropo-
myosin expression in vertebrate hearts as well as to find
out the functional role of TPM1κ.
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